Our studies suggest that small molecule agonists of GPR18 might augment the size of the KLRG1+ effector CD8 T cell compartment, an effect that might be beneficial, for example, during viral responses or in the context of tumor immunotherapy. This evidence concerns the gene CD8A and neoplasm.